Form 4: Director David Green Receives Stock Options in Harvard Apparatus Regenerative Technology, Inc.

David Green, a director at Harvard Apparatus Regenerative Technology, Inc. (HRGN), was granted stock options on June 27, 2024, as part of his annual equity grant and in lieu of cash compensation.

Summary

• On June 27, 2024, David Green, a director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), received two stock option grants.
• The first grant was for 10,204 shares at an exercise price of $2.92, representing his annual equity grant as a non-employee director, vesting in four equal installments.
• The vesting dates for the first grant are September 27, 2024, December 27, 2024, March 27, 2025, and June 27, 2025.
• The second grant was for 8,215 shares at an exercise price of $2.92, granted in lieu of cash compensation, vesting in four equal installments.
• The vesting dates for the second grant are June 27, 2024, June 30, 2024, September 30, 2024, and December 31, 2024.
• Both stock options expire on June 27, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a standard practice.

Positives

• The grants align director compensation with company performance.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of compensation for directors, especially in smaller companies, to align their interests with shareholders.

Stakeholder Impact

• The stock option grants may have a minor dilutive effect on existing shareholders.

Key Dates